Developmental brain abnormalities in tuberous sclerosis complex: A comparative tissue analysis of cortical tubers and perituberal cortex

Epilepsia

Volumn 55, Issue 4, 2014, Pages 539-550

  Ruppe, Véronique ^a   Dilsiz, Pelin ^a   Reiss, Carol Shoshkes ^b   Carlson, Chad ^a,c   Devinsky, Orrin ^a   Zagzag, David ^c   Weiner, Howard L ^c   Talos, Delia M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Axons; Epileptogenesis; Hypomyelination; Mammalian target of rapamycin; Peri tuber

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN S6;

ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL TUBER; FEMALE; GIANT CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MYELINATION; NERVE CELL NETWORK; NERVE FIBER GROWTH; PERITUBERAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TUBEROUS SCLEROSIS; WESTERN BLOTTING; BRAIN; BRAIN DISEASES; COMPARATIVE STUDY; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY;

BRAIN; BRAIN DISEASES; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; TUBEROUS SCLEROSIS;

EID: 84899490503     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12545     Document Type: Article

References (73)

1. Crino PB, Nathanson KL, Henske EP,. The tuberous sclerosis complex. N Engl J Med 2006; 355: 1345-1356.
2. Sarnat HB, Flores-Sarnat L,. Neuropathology of pediatric epilepsy. Handb Clin Neurol 2013; 111: 399-416.
3. Crino PB, Trojanowski JQ, Dichter MA, et al. Embryonic neuronal markers in tuberous sclerosis: single-cell molecular pathology. Proc Natl Acad Sci U S A 1996; 93: 14152-14157.
4. Talos DM, Kwiatkowski DJ, Cordero K, et al. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann Neurol 2008; 63: 454-465.
5. Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51: 1236-1241.
6. de Vries PJ, Hunt A, Bolton PF,. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur Child Adolesc Psychiatry 2007; 16: 16-24.
7. Numis AL, Major P, Montenegro MA, et al. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology 2011; 76: 981-987.
8. Weiner HL, Carlson C, Ridgway EB, et al. Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach. Pediatrics 2006; 117: 1494-1502.
9. Major P, Rakowski S, Simon MV, et al. Are cortical tubers epileptogenic? Evidence from electrocorticography. Epilepsia 2009; 50: 147-154.
10. Ma TS, Carlson C, Elliott R, et al. Electrocorticographic evidence of TSC perituberal epileptogenicity. J Neurosurg Pediatr 2012; 10: 376-382.
11. Chandra PS, Salamon N, Huang J, et al. FDG-PET/MRI coregistration and diffusion-tensor imaging distinguish epileptogenic tubers and cortex in patients with tuberous sclerosis complex: a preliminary report. Epilepsia 2006; 47: 1543-1549.
12. Madhavan D, Weiner HL, Carlson C, et al. Local epileptogenic networks in tuberous sclerosis complex: a case review. Epilepsy Behav 2007; 11: 140-146.
13. Jansen FE, Vincken KL, Algra A, et al. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology 2008; 70: 916-923.
14. Krishnan ML, Commowick O, Jeste SS, et al. Diffusion features of white matter in tuberous sclerosis with tractography. Pediatr Neurol 2010; 42: 101-106.
15. Widjaja E, Simao G, Mahmoodabadi SZ, et al. Diffusion tensor imaging identifies changes in normal-appearing white matter within the epileptogenic zone in tuberous sclerosis complex. Epilepsy Res 2010; 89: 246-253.
16. Boer K, Troost D, Jansen F, et al. Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex. Neuropathology 2008; 28: 577-590.
17. Marcotte L, Aronica E, Baybis M, et al. Cytoarchitectural alterations are widespread in cerebral cortex in tuberous sclerosis complex. Acta Neuropathol 2012; 123: 685-693.
18. Peters JM, Sahin M, Vogel-Farley VK, et al. Loss of white matter microstructural integrity is associated with adverse neurological outcome in tuberous sclerosis complex. Acad Radiol 2012; 19: 17-25.
19. Laplante M, Sabatini DM,. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
20. Ma XM, Blenis J,. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 307-318.
21. Tavazoie SF, Alvarez VA, Ridenour DA, et al. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci 2005; 8: 1727-1734.
22. Goto J, Talos DM, Klein P, et al. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci U S A 2011; 108: E1070-E1079.
23. Wang Y, Greenwood JS, Calcagnotto ME, et al. Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1. Ann Neurol 2007; 61: 139-152.
24. Choi YJ, Di Nardo A, Kramvis I, et al. Tuberous sclerosis complex proteins control axon formation. Genes Dev 2008; 22: 2485-2495.
25. Nie D, Di Nardo A, Han JM, et al. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci 2010; 13: 163-172.
26. Bateup HS, Takasaki KT, Saulnier JL, et al. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J Neurosci 2011; 31: 8862-8869.
27. Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008; 14: 843-848.
28. White R, Hua Y, Scheithauer B, et al. Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers. Ann Neurol 2001; 49: 67-78.
29. Talos DM, Sun H, Kosaras B, et al. Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia. Ann Neurol 2012a; 71: 539-551.
30. Cepeda C, Hurst RS, Flores-Hernandez J, et al. Morphological and electrophysiological characterization of abnormal cell types in pediatric cortical dysplasia. J Neurosci Res 2003; 72: 472-486.
31. Cepeda C, Andre VM, Yamazaki I, et al. Comparative study of cellular and synaptic abnormalities in brain tissue samples from pediatric tuberous sclerosis complex and cortical dysplasia type II. Epilepsia 2010; 51 (Suppl. 3): 160-165.
32. Carson RP, Van Nielen DL, Winzenburger PA, et al. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. Neurobiol Dis 2012; 45: 369-380.
33. Meikle L, Pollizzi K, Egnor A, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008; 28: 5422-5432.
34. Palmini A, Najm I, Avanzini G, et al. Terminology and classification of the cortical dysplasias. Neurology 2004; 62: S2-S8.
35. Zagzag D, Krishnamachary B, Yee H, et al. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005; 65: 6178-6188.
36. Klopfleisch R,. Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology-a systematic review. BMC Vet Res 2013; 9: 123.
37. Talos DM, Sun H, Zhou X, et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS ONE 2012b; 7: e35885.
38. Sarnat HB, Flores-Sarnat L,. Radial microcolumnar cortical architecture: maturational arrest or cortical dysplasia? Pediatr Neurol 2013b; 48: 259-270.
39. Meikle L, Talos DM, Onda H, et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 2007; 27: 5546-5558.
40. Ulfig N, Nickel J, Bohl J,. Monoclonal antibodies SMI 311 and SMI 312 as tools to investigate the maturation of nerve cells and axonal patterns in human fetal brain. Cell Tissue Res 1998; 291: 433-443.
41. Mathern GW, Leite JP, Pretorius JK, et al. Children with severe epilepsy: evidence of hippocampal neuron losses and aberrant mossy fiber sprouting during postnatal granule cell migration and differentiation. Brain Res Dev Brain Res 1994; 78: 70-80.
42. Salin P, Tseng GF, Hoffman S, et al. Axonal sprouting in layer V pyramidal neurons of chronically injured cerebral cortex. J Neurosci 1995; 15: 8234-8245.
43. Haynes RL, Borenstein NS, Desilva TM, et al. Axonal development in the cerebral white matter of the human fetus and infant. J Comp Neurol 2005; 484: 156-167.
44. Mullen RJ, Buck CR, Smith AM,. NeuN, a neuronal specific nuclear protein in vertebrates. Development 1992; 116: 201-211.
45. Benowitz LI, Routtenberg A,. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 1997; 20: 84-91.
46. Billiards SS, Haynes RL, Folkerth RD, et al. Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. Brain Pathol 2008; 18: 153-163.
47. Mohamed AR, Bailey CA, Freeman JL, et al. Intrinsic epileptogenicity of cortical tubers revealed by intracranial EEG monitoring. Neurology 2012; 79: 2249-2257.
48. Crino PB,. mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 2011; 17: 734-742.
49. Yuan E, Tsai PT, Greene-Colozzi E, et al. Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features. Hum Mol Genet 2012; 21: 4286-4300.
50. Zeng LH, Rensing NR, Zhang B, et al. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet 2011; 20: 445-454.
51. Zeng LH, Xu L, Gutmann DH, et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008; 63: 444-453.
52. Tsai V, Parker WE, Orlova KA, et al. Fetal brain mTOR signaling activation in tuberous sclerosis complex. Cereb Cortex 2014; 24 (2): 315-327.
53. Tsai PT, Hull C, Chu Y, et al. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 2012; 488: 647-651.
54. Ruegg S, Baybis M, Juul H, et al. Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res 2007; 77: 85-92.
55. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811.
56. Carson RP, Fu C, Winzenburger P, et al. Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex. Hum Mol Genet 2013; 22: 140-152.
57. Huang J, Wu S, Wu CL, et al. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res 2009; 69: 6107-6114.
58. Makki MI, Chugani DC, Janisse J, et al. Characteristics of abnormal diffusivity in normal-appearing white matter investigated with diffusion tensor MR imaging in tuberous sclerosis complex. AJNR Am J Neuroradiol 2007; 28: 1662-1667.
59. O'Kusky JR, Akers MA, Vinters HV,. Synaptogenesis in hemimegalencephaly: the numerical density of asymmetric and symmetric synapses in the cerebral cortex. Acta Neuropathol 1996; 92: 156-163.
60. Aronica E, Boer K, Baybis M, et al. Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly. Acta Neuropathol 2007; 114: 287-293.
61. Goldman-Rakic PS,. Development of cortical circuitry and cognitive function. Child Dev 1987; 58: 601-622.
62. Chu Y, Jin X, Parada I, et al. Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proc Natl Acad Sci U S A 2010; 107: 7975-7980.
63. Tessier CR, Broadie K,. Drosophila fragile X mental retardation protein developmentally regulates activity-dependent axon pruning. Development 2008; 135: 1547-1557.
64. Danzer SC, He X, Loepke AW, et al. Structural plasticity of dentate granule cell mossy fibers during the development of limbic epilepsy. Hippocampus 2010; 20: 113-124.
65. Prince DA, Parada I, Graber K,. Traumatic brain injury and posttraumatic epilepsy. In, Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta Delgado-Escueta, (Eds) Jasper's basic mechanisms of the epilepsies. 4th Ed. National Center for Biotechnology Information (US), Bethesda, MD: 2012:pp. 315-330.
66. Babb TL, Kupfer WR, Pretorius JK, et al. Synaptic reorganization by mossy fibers in human epileptic fascia dentata. Neuroscience 1991; 42: 351-363.
67. Piaton G, Gould RM, Lubetzki C,. Axon-oligodendrocyte interactions during developmental myelination, demyelination and repair. J Neurochem 2010; 114: 1243-1260.
68. Konopka A, Grajkowska W, Ziemianska K, et al. Matrix metalloproteinase-9 (MMP-9) in human intractable epilepsy caused by focal cortical dysplasia. Epilepsy Res 2013; 104: 45-58.
69. Colognato H, Galvin J, Wang Z, et al. Identification of dystroglycan as a second laminin receptor in oligodendrocytes, with a role in myelination. Development 2007; 134: 1723-1736.
70. Kaplan MR, Meyer-Franke A, Lambert S, et al. Induction of sodium channel clustering by oligodendrocytes. Nature 1997; 386: 724-728.
71. Brady ST, Witt AS, Kirkpatrick LL, et al. Formation of compact myelin is required for maturation of the axonal cytoskeleton. J Neurosci 1999; 19: 7278-7288.
72. Trapp BD, Stys PK,. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280-291.
73. Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011; 52: 158-174.